25 Apr 2021
In amyotrophic lateral sclerosis and frontotemporal dementia, loss of the RNA-binding protein TDP-43 from the nucleus creates a surge of mis-spliced mRNAs in neurons. So far, only one of these errant transcripts, stathmin-2, has been tied to disease pathology. Now, two preprints uploaded to bioRXiv on April 4 detail another UNC13A. Variants in this gene increase risk for ALS/FTD.
Neurons lacking nuclear TDP-43 mis-splice UNC13A, make less of the protein.
UNC13A risk variants incorporate cryptic exons.
This only occurs in brain and spinal cord tissue harboring TDP-43 deposits.
One paper was penned by researchers led by Pietro Fratta, University College London, and Michael Ward, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. The second is from the labs of Aaron Gitler, Stanford University, California, and Leonard Petrucelli, Mayo Clinic, Jacksonville, Florida. Both papers report that if TDP-43 binding to UNC13A falters, the transcript is m
CND Life Sciences Partners With FFF Enterprises And NuFactor
Strategic Collaboration Educates Neurology Community About Syn-One Test™
News provided by
Share this article
Share this article
PHOENIX and TEMECULA, Calif., April 22, 2021 /PRNewswire/ CND Life Sciences, Inc., an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, announced today its national collaboration with NuFactor
®, a specialty infusion company and subsidiary of FFF Enterprises, Inc., to educate neurologists on the availability and application of the Syn-One Test™.
The collaboration focuses on engaging neuromuscular specialists and general neurologists in the U.S. who treat patients with signs and symptoms of synucleinopathies, including Parkinson s disease, multiple system atrophy, and pure autonomic failure. For a significant percentage of patients, physicians lack objective pathological proof to help conf
Long-term Benefit for DBS in Treating Parkinson s Motor Symptoms medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
Two of the nation s top NIH experts Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, and Walter Koroshetz, MD, director of the National Institute of Neurological Disorders and Stroke (NINDS) joined American Academy of Neurology (AAN) science committee leaders in special session about COVID-19 at the AAN annual meeting.
Of particular interest to neurologists were questions about COVID vaccines, nervous system involvement during acute infection, and symptoms like brain fog and fatigue that linger for months. Fauci and Koroshetz touched upon those and other topics. Here are a few highlights of their discussion.
d=0.56,
P=0.04).
However, this therapy didn t evoke a behavioral benefit, as measured by Behavioral Pathology in Alzheimer Disease Rating Scale scores (
z=0.18,
P=0.86), according to the researchers.
Men saw no cognitive nor behavioral benefit with six weeks of sodium benzoate treatment in the analysis, they noted.
Sodium benzoate acts as an indirect NMDA receptor (NMDAR) enhancer. It is most commonly used as a preservative in packaged and processed foods and beverages. The chemical compound, which appears as a crystalline powder, is made from combining benzoic acid and sodium hydroxide.
The authors reported that there were some slight hormonal changes in women in the study, as benzoate treatment was significantly tied to an increase in estradiol to follicle-stimulating hormone (FSH) ratios in women compared with those on placebo (mean difference between baseline and endpoint 0 versus -0.1 with placebo,